Lista de obras - Milena Cannella - Dominio Público Uruguay

Abnormal morphology of peripheral cell tissues from patients with Huntington disease

artículo científico publicado en 2009

Alterations in the α2 δ ligand, thrombospondin-1, in a rat model of spontaneous absence epilepsy and in patients with idiopathic/genetic generalized epilepsies.

artículo científico publicado en 2017

Analgesia induced by the epigenetic drug, L-acetylcarnitine, outlasts the end of treatment in mouse models of chronic inflammatory and neuropathic pain

artículo científico publicado en 2017

CAG mutation effect on rate of progression in Huntington's disease.

artículo científico publicado en 2002

Cavernous angiomas of the nervous system in Italy: clinical and genetic study

article

Changes in mGlu5 receptor-dependent synaptic plasticity and coupling to homer proteins in the hippocampus of Ube3A hemizygous mice modeling angelman syndrome

artículo científico publicado en 2014

Changes in the expression of genes encoding for mGlu4 and mGlu5 receptors and other regulators of the indirect pathway in acute mouse models of drug-induced parkinsonism.

artículo científico publicado en 2015

DNA instability in replicating Huntington's disease lymphoblasts

artículo científico publicado en 2009

De novo seven extra repeat expanded mutation in the PRNP gene in an Italian patient with early onset dementia.

artículo científico publicado en 2009

De novo seven extra repeat expanded mutation in the PRNP gene in an Italian patient with early onset dementia.

artículo científico publicado en 2007

Dickkopf-3 Upregulates VEGF in Cultured Human Endothelial Cells by Activating Activin Receptor-Like Kinase 1 (ALK1) Pathway

artículo científico publicado en 2017

Distinct brain volume changes correlating with clinical stage, disease progression rate, mutation size, and age at onset prediction as early biomarkers of brain atrophy in Huntington's disease

artículo científico publicado en 2009

Early defect of transforming growth factor β1 formation in Huntington's disease.

artículo científico publicado en 2011

Functional partnership between mGlu3 and mGlu5 metabotropic glutamate receptors in the central nervous system

artículo científico publicado en 2017

Genetic deletion of mGlu2 metabotropic glutamate receptors improves the short-term outcome of cerebral transient focal ischemia.

artículo científico publicado en 2017

Genotype-dependent priming to self- and xeno-cannibalism in heterozygous and homozygous lymphoblasts from patients with Huntington's disease

artículo científico publicado en 2006

Highly disabling cerebellar presentation in Huntington disease.

artículo científico publicado en 2003

Highly variable penetrance in subjects affected with cavernous cerebral angiomas (CCM) carrying novel CCM1 and CCM2 mutations.

artículo científico publicado en 2007

Homozygosity for CAG mutation in Huntington disease is associated with a more severe clinical course

artículo científico publicado en 2003

Huntington disease in subjects from an Israeli Karaite community carrying alleles of intermediate and expanded CAG repeats in the HTT gene: Huntington disease or phenocopy?

artículo científico publicado en 2008

Impaired PGC-1alpha function in muscle in Huntington's disease.

scientific article published on 21 May 2009

Italian Huntington disease patients--data and tissue bank.

artículo científico publicado en 2003

Localization of autosomal recessive early-onset parkinsonism to chromosome 1p36 (PARK7) in an independent dataset

artículo científico publicado en 2002

Low brain-derived neurotrophic factor (BDNF) levels in serum of Huntington's disease patients.

artículo científico publicado en 2007

Molecular medicine: predicting and preventing Huntington's disease.

artículo científico publicado en 2008

Mutations in a gene encoding a novel protein containing a phosphotyrosine-binding domain cause type 2 cerebral cavernous malformations

artículo científico publicado en 2003

N-Acetyl-cysteine causes analgesia by reinforcing the endogenous activation of type-2 metabotropic glutamate receptors.

artículo científico publicado en 2012

Onset and pre-onset studies to define the Huntington's disease natural history.

artículo científico publicado en 2001

Pharmacological enhancement of mGlu1 metabotropic glutamate receptors causes a prolonged symptomatic benefit in a mouse model of spinocerebellar ataxia type 1.

artículo científico publicado en 2013

Predictive testing for persons at risk for homozygosity for CAG expansion in the Huntington disease gene.

artículo científico publicado en 2003

Presymptomatic tests in Huntington's disease and dominant ataxias.

artículo científico publicado en 2001

Reduced activity of cortico-striatal fibres in the R6/2 mouse model of Huntington's disease.

artículo científico publicado en 2007

Riluzole protects Huntington disease patients from brain glucose hypometabolism and grey matter volume loss and increases production of neurotrophins.

artículo científico publicado en 2009

Severe ultrastructural mitochondrial changes in lymphoblasts homozygous for Huntington disease mutation

artículo científico publicado en 2005

Targeting group II metabotropic glutamate (mGlu) receptors for the treatment of psychosis associated with Alzheimer's disease: selective activation of mGlu2 receptors amplifies beta-amyloid toxicity in cultured neurons, whereas dual activation of mG

artículo científico publicado en 2010

Targeting type-2 metabotropic glutamate receptors to protect vulnerable hippocampal neurons against ischemic damage.

artículo científico publicado en 2015

The platelet maximum number of A2A-receptor binding sites (Bmax) linearly correlates with age at onset and CAG repeat expansion in Huntington's disease patients with predominant chorea.

artículo científico publicado en 2005

Lista de obras de Milena Cannella

Abnormal morphology of peripheral cell tissues from patients with Huntington disease

Alterations in the α2 δ ligand, thrombospondin-1, in a rat model of spontaneous absence epilepsy and in patients with idiopathic/genetic generalized epilepsies.

Analgesia induced by the epigenetic drug, L-acetylcarnitine, outlasts the end of treatment in mouse models of chronic inflammatory and neuropathic pain

CAG mutation effect on rate of progression in Huntington's disease.

Cavernous angiomas of the nervous system in Italy: clinical and genetic study

Changes in mGlu5 receptor-dependent synaptic plasticity and coupling to homer proteins in the hippocampus of Ube3A hemizygous mice modeling angelman syndrome

Changes in the expression of genes encoding for mGlu4 and mGlu5 receptors and other regulators of the indirect pathway in acute mouse models of drug-induced parkinsonism.

DNA instability in replicating Huntington's disease lymphoblasts

De novo seven extra repeat expanded mutation in the PRNP gene in an Italian patient with early onset dementia.

De novo seven extra repeat expanded mutation in the PRNP gene in an Italian patient with early onset dementia.

Dickkopf-3 Upregulates VEGF in Cultured Human Endothelial Cells by Activating Activin Receptor-Like Kinase 1 (ALK1) Pathway

Distinct brain volume changes correlating with clinical stage, disease progression rate, mutation size, and age at onset prediction as early biomarkers of brain atrophy in Huntington's disease

Early defect of transforming growth factor β1 formation in Huntington's disease.

Functional partnership between mGlu3 and mGlu5 metabotropic glutamate receptors in the central nervous system

Genetic deletion of mGlu2 metabotropic glutamate receptors improves the short-term outcome of cerebral transient focal ischemia.

Genotype-dependent priming to self- and xeno-cannibalism in heterozygous and homozygous lymphoblasts from patients with Huntington's disease

Highly disabling cerebellar presentation in Huntington disease.

Highly variable penetrance in subjects affected with cavernous cerebral angiomas (CCM) carrying novel CCM1 and CCM2 mutations.

Homozygosity for CAG mutation in Huntington disease is associated with a more severe clinical course

Huntington disease in subjects from an Israeli Karaite community carrying alleles of intermediate and expanded CAG repeats in the HTT gene: Huntington disease or phenocopy?

Impaired PGC-1alpha function in muscle in Huntington's disease.

Italian Huntington disease patients--data and tissue bank.

Localization of autosomal recessive early-onset parkinsonism to chromosome 1p36 (PARK7) in an independent dataset

Low brain-derived neurotrophic factor (BDNF) levels in serum of Huntington's disease patients.

Molecular medicine: predicting and preventing Huntington's disease.

Mutations in a gene encoding a novel protein containing a phosphotyrosine-binding domain cause type 2 cerebral cavernous malformations

N-Acetyl-cysteine causes analgesia by reinforcing the endogenous activation of type-2 metabotropic glutamate receptors.

Onset and pre-onset studies to define the Huntington's disease natural history.

Pharmacological enhancement of mGlu1 metabotropic glutamate receptors causes a prolonged symptomatic benefit in a mouse model of spinocerebellar ataxia type 1.

Predictive testing for persons at risk for homozygosity for CAG expansion in the Huntington disease gene.

Presymptomatic tests in Huntington's disease and dominant ataxias.

Reduced activity of cortico-striatal fibres in the R6/2 mouse model of Huntington's disease.

Riluzole protects Huntington disease patients from brain glucose hypometabolism and grey matter volume loss and increases production of neurotrophins.

Severe ultrastructural mitochondrial changes in lymphoblasts homozygous for Huntington disease mutation

Targeting group II metabotropic glutamate (mGlu) receptors for the treatment of psychosis associated with Alzheimer's disease: selective activation of mGlu2 receptors amplifies beta-amyloid toxicity in cultured neurons, whereas dual activation of mG

Targeting type-2 metabotropic glutamate receptors to protect vulnerable hippocampal neurons against ischemic damage.

The platelet maximum number of A2A-receptor binding sites (Bmax) linearly correlates with age at onset and CAG repeat expansion in Huntington's disease patients with predominant chorea.